中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝性脑病中医/壮医“浊毒致病”理论及防治策略的构建与实践

吴智鹏,  张钰琴,  姚春,  王明刚,  王娜,  彭梦如,  磨宁芳,  郑娅晴,  张荣臻,  毛德文

PDF下载 ( 923 KB)
文章导航 > 临床肝胆病杂志  > 2025 >  41(2): 370-374
引用本文:
shu
Citation:
shu

肝性脑病中医/壮医“浊毒致病”理论及防治策略的构建与实践

DOI: 10.12449/JCH250226
  • 1.

    广西中医药大学第一附属医院肝病一区，南宁 530023

  • 2.

    广西医科大学基础医学院，南宁 530021

  • 3.

    中国中医科学院广安门医院针灸科，北京 100053

基金项目: 

国家自然科学基金 (82160881);

国家自然科学基金 (82260899);

广西重点研发计划项目 (Guike AB22035076);

广西中医药大学“岐黄工程”高层次人才团队培育项目 (202409);

广西中医药大学桂派中医药传承创新团队项目 (2022A001);

广西中医药大学第一附属医院青年拔尖人才培养对象资助项目 (yuandangzi［2022］46)

利益冲突声明：本文不存在任何利益冲突。
作者贡献声明：吴智鹏、张钰琴负责撰写论文；彭梦如、磨宁芳、郑娅晴参与修改论文；姚春、王明刚、王娜负责拟定写作思路；毛德文、张荣臻指导撰写文章并最后定稿。
详细信息
    通信作者:

    张荣臻， zhangrongzhen2007@163.com （ORCID： 0000-0003-2243-665X）

    毛德文， mdwboshi2005@163.com （ORCID： 0000-0001-9438-9325）

Construction and practice of the theory of “turbid toxin pathogenesis” and related prevention and treatment strategies for hepatic encephalopathy in traditional Chinese medicine/Zhuang medicine

  • 1.

    First Ward of Hepatology，The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530023，China

  • 2.

    School of Pre-clinical Medicine，Guangxi Medical University，Nanning 530021，China

  • 3.

    Department of Acupuncture and Moxibustion，Guang’anmen Hospital，China Academy of Chinese Medical Sciences，Beijing 100053，China

Research funding: 

National Natural Science Foundation of China (82160881);

National Natural Science Foundation of China (82260899);

Guangxi Key Research and Development Plan Project (Guike AB22035076);

Guangxi University of Chinese Medicine ‘Qihuang Project’ High-Level Talent Team Training Project (202409);

Guangxi University of Chinese Medicine Inheritance Innovation Team Project (2022A001);

The First Affiliated Hospital of Guangxi University of Chinese Medicine Youth Top-Notch Talent Training Object Funding Project (yuandangzi［2022］46)

More Information

    摘要
  • 摘要: 肝性脑病为肝病领域的疑难危重疾病，进展迅速、治疗手段有限、发病机制亟待突破。选择合适的防治策略，对于延缓疾病进展、降低发病率和病死率起到重要作用。本文就中医/壮医肝性脑病“浊毒致病”理论及防治策略进行述评，提出肝性脑病中医/壮医“浊毒致病”新学说，解析“浊”“毒”及“浊毒致病”理论的科学内涵，构建肝性脑病“四步曲”防治策略，并以此为基础延伸出以“四方两技法”为代表的肝性脑病临床防治新方案，继而阐明核心方药与技法防治肝性脑病的效应机制与生物学基础，以期为肝性脑病的防治提供参考。

     

    Abstract: Hepatic encephalopathy is a difficult and critical disease with rapid progression and limited treatment methods in the field of liver disease， and it is urgently needed to make breakthroughs in its pathogenesis. Selection of appropriate prevention and treatment strategies is of great importance in delaying disease progression and reducing the incidence and mortality rates. This article reviews the theory of “turbid toxin pathogenesis” and related prevention and treatment strategies for hepatic encephalopathy in traditional Chinese medicine/Zhuang medicine， proposes a new theory of “turbid toxin pathogenesis”， analyzes the scientific connotations of “turbid”， “toxin”， and the theory of “turbid toxin pathogenesis”， and constructs the “four-step” prevention and treatment strategies for hepatic encephalopathy， thereby establishing the new clinical prevention and treatment regimen for hepatic encephalopathy represented by “four prescriptions and two techniques” and clarifying the effect mechanism and biological basis of core prescriptions and techniques in the prevention and treatment of hepatic encephalopathy， in order to provide a reference for the prevention and treatment of hepatic encephalopathy.

     

    • HTML全文

  • 图  1  肝性脑病“浊毒致病”理论的中/壮医防治策略及关键方案

    Figure  1.  The prevention and treatment strategies and key technique of Chinese / Zhuang medicine based on the theory of ' Turbid Toxin Pathogenic ' of hepatic encephalopathy

    下载: 全尺寸图片 幻灯片
    • 参考文献(30)
  • [1] ROSE CF, AMODIO P, BAJAJ JS, et al. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy[J]. J Hepatol, 2020, 73( 6): 1526- 1547. DOI: 10.1016/j.jhep.2020.07.013.
    [2] TAPPER EB, PARIKH ND. Diagnosis and management of cirrhosis and its complications: A review[J]. JAMA, 2023, 329( 18): 1589- 1602. DOI: 10.1001/jama.2023.5997.
    [3] WANG XB, SHI K. Integrated traditional Chinese and western medicine diagnosis and treatment of hepatic encephalopathy: Advances and perspectives[J]. J Clin Hepatol, 2022, 38( 9): 1969- 1973. DOI: 10.3969/j.issn.1001-5256.2022.09.004.

    王宪波, 时克. 肝性脑病的中西医结合诊疗进展与展望[J]. 临床肝胆病杂志, 2022, 38( 9): 1969- 1973. DOI: 10.3969/j.issn.1001-5256.2022.09.004.
    [4] WAN LF. Clinical experience of chief physician SHAO Ming treating hepatic encephalopathy[J]. J Chengdu Univ Tradit Chin Med, 2010, 33( 3): 38, 44. DOI: 10.13593/j.cnki.51-1501/r.2010.03.010.

    万凌峰. 邵铭主任医师辨证论治肝性脑病经验[J]. 成都中医药大学学报, 2010, 33( 3): 38, 44. DOI: 10.13593/j.cnki.51-1501/r.2010.03.010.
    [5] JIANG HN, MAO DW, YE QL, et al. Research progress on TCM syndrome differentiation and treatment of hepatic encephalopathy[J]. Shaanxi J Tradit Chin Med, 2020, 41( 11): 1678- 1680. DOI: 10.3969/j.issn.1000-7369.2020.11.042.

    蒋海南, 毛德文, 叶倩伶, 等. 中医辨证论治肝性脑病研究进展[J]. 陕西中医, 2020, 41( 11): 1678- 1680. DOI: 10.3969/j.issn.1000-7369.2020.11.042.
    [6] PANG YZ, LI WW. Zhuang Medicine internal pediatrics[M]. Beijing: China Press of Traditional Chinese Medicine, 2018.

    庞宇舟, 李伟伟. 壮医内儿科学[M]. 北京: 中国中医药出版社, 2018.
    [7] BAI WJ, PAN PP, SHI QL, et al. Discussion on the pathogenic theory of“turbidity-toxin” in hepatic encephalopathy[J]. J Basic Chin Med, 2023, 29( 5): 727- 730. DOI: 10.19945/j.cnki.issn.1006-3250.2023.05.005.

    柏文婕, 潘佩佩, 石清兰, 等. 基于“浊毒致病”学说探讨肝性脑病病因病机[J]. 中国中医基础医学杂志, 2023, 29( 5): 727- 730. DOI: 10.19945/j.cnki.issn.1006-3250.2023.05.005.
    [8] Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol, 2018, 34( 10): 2076- 2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007.

    中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志, 2018, 34( 10): 2076- 2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007.
    [9] LIN Y, YAN GJ, FENG F, et al. Characterization of intestinal microbiota and serum metabolites in patients with mild hepatic encephalopathy[J]. Open Life Sci, 2022, 17( 1): 139- 154. DOI: 10.1515/biol-2021-0140.
    [10] TANG YF, LIU XD, WANG WX, et al. Clinical characteristics and relatedinfluencing factors of minimalhepatic encephalopathy in patients with liver cirrhosis[J]. Infect Dis Inf, 2022, 35( 4): 316- 320. DOI: 10.3969/j.issn.1007-8134.2022.04.006.

    唐艳芳, 刘旭东, 王文鑫, 等. 肝硬化合并轻微型肝性脑病的临床特点以及相关影响因素分析[J]. 传染病信息, 2022, 35( 4): 316- 320. DOI: 10.3969/j.issn.1007-8134.2022.04.006.
    [11] WANG TS, ZHANG RZ, WANG MG, et al. Theoretical connotations of liver failure“toxic pathogen-toxic turbidity” theory from the angle of“gut-liver axis”[J]. West J Tradit Chin Med, 2022, 35( 6): 67- 70. DOI: 10.12174/j.issn.2096-9600.2022.06.18.

    王挺帅, 张荣臻, 王明刚, 等. 从“肠肝轴”角度诠释肝衰竭“毒邪-毒浊”学说的理论内涵[J]. 西部中医药, 2022, 35( 6): 67- 70. DOI: 10.12174/j.issn.2096-9600.2022.06.18.
    [12] SHI QL, HUANG ZH, BAI WJ, et al. Construction and practice of“four-step”prevention and treatment strategy for hepatic encephalopathy[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 2): 166- 168. DOI: 10.3969/j.issn.1005-0264.2023.002.019.

    石清兰, 黄祖鸿, 柏文婕, 等. 肝性脑病“四步曲”防治策略的构建与实践[J]. 中西医结合肝病杂志, 2023, 33( 2): 166- 168. DOI: 10.3969/j.issn.1005-0264.2023.002.019.
    [13] WANG S, WANG N, MAO DW, et al. Clinical observation on the effect of Liuwei xingshen granules combined with mirabilite retention Enema in the treatment of type C hepatic encephalopathy and the regulation of acid-base imbalance[J]. Tradit Chin Med J, 2023, 22( 11): 28- 31. DOI: 10.14046/j.cnki.zyytb2002.2023.11.015.

    王沙, 王娜, 毛德文, 等. 六味醒神颗粒加芒硝保留灌肠治疗C型肝性脑病及调节酸碱失衡作用的临床观察[J]. 中医药通报, 2023, 22( 11): 28- 31. DOI: 10.14046/j.cnki.zyytb2002.2023.11.015.
    [14] YAO C, XIE W, FU L. Jiedu Huayu Decoction science, learning and memory in the rats' behavior of the minor hepatic encephalopathy, toxins, ammonia, liver function and liver pathology affect plasma randomized controlled research[J]. J Pract Tradit Chin Intern Med, 2012, 26( 5): 7- 10. DOI: 10.3969/j.issn.1671-7813.2012.05.04.

    姚春, 谢武, 付蕾. 解毒化瘀方对轻微型肝性脑病大鼠行为学、学习记忆能力、血浆内毒素、血氨、肝功能及肝脏病理影响随机平行对照研究[J]. 实用中医内科杂志, 2012, 26( 5): 7- 10. DOI: 10.3969/j.issn.1671-7813.2012.05.04.
    [15] LYU C, MAO DW, QIN Q, et al. Effect of Wenyang Huayu Tuihuang Decoction in the treatment of hepatitis B-related chronic and acute liver failure[J]. China Med Herald, 2019, 16( 30): 142- 146.

    吕超, 毛德文, 覃倩, 等. 温阳化瘀退黄方治疗乙型肝炎相关慢加急性肝衰竭的效果[J]. 中国医药导报, 2019, 16( 30): 142- 146.
    [16] MA YZ, MAO DW, QIN YX, et al. Clinical effects of Liuwei xingshen granules in treating mild hepatic encephalopathy of liver cirrhosis and its influence on blood ammonia and endotoxin[J]. West J Tradit Chin Med, 2021, 34( 5): 7- 10. DOI: 10.12174/j.issn.2096-9600.2021.05.03.

    马玉珍, 毛德文, 覃艳新, 等. 六味醒神颗粒治疗肝硬化轻微型肝性脑病的临床疗效及其对血氨和内毒素的影响[J]. 西部中医药, 2021, 34( 5): 7- 10. DOI: 10.12174/j.issn.2096-9600.2021.05.03.
    [17] WANG MG, WANG N, MAO DW, et al. The clinical research into minimal hepatic encephalopathy treated with Liuwei xingshen granule[J]. Henan Tradit Chin Med, 2016, 36( 12): 2112- 2114. DOI: 10.16367/j.issn.1003-5028.2016.12.0843.

    王明刚, 王娜, 毛德文, 等. 六味醒神颗粒治疗轻微型肝性脑病临床研究[J]. 河南中医, 2016, 36( 12): 2112- 2114. DOI: 10.16367/j.issn.1003-5028.2016.12.0843.
    [18] WANG MG, MAO DW, WANG N, et al. Experimental study on regulating blood-brain barrier permeability of rats with mild hepatic encephalopathy by Liuwei Xingshen Granule[J]. Lishizhen Med Mater Med Res, 2016, 27( 7): 1619- 1621. DOI: 10.3969/j.issn.1008-0805.2016.07.027.

    王明刚, 毛德文, 王娜, 等. 六味醒神颗粒调控轻微型肝性脑病大鼠血脑屏障通透性的实验研究[J]. 时珍国医国药, 2016, 27( 7): 1619- 1621. DOI: 10.3969/j.issn.1008-0805.2016.07.027.
    [19] WU N, MAO XK, WANG MG. Molecular mechanism of Liuwei xingshen granule(六味醒神颗粒) against hepatic encephalopathy based on network pharmacology and molecular docking[J]. Guid J Tradit Chin Med Pharm, 2020, 26( 5): 88- 92. DOI: 10.13862/j.cnki.cn43-1446/r.2020.05.023.

    吴娜, 毛祥坤, 王明刚. 基于网络药理学及分子对接研究六味醒神颗粒治疗肝性脑病的分子作用机制[J]. 中医药导报, 2020, 26( 5): 88- 92. DOI: 10.13862/j.cnki.cn43-1446/r.2020.05.023.
    [20] HUANG GY, MAO DW, LONG FL, et al. Retention Enema with rhubarb decoction in treating hepatic encephalopathy: Results from a multi-center clinical trial[J]. Liaoning J Tradit Chin Med, 2011, 38( 7): 1364- 1366. DOI: 10.13192/j.ljtcm.2011.07.118.huanggy.032.

    黄古叶, 毛德文, 龙富立, 等. 大黄煎剂保留灌肠治疗肝性脑病的多中心临床研究[J]. 辽宁中医杂志, 2011, 38( 7): 1364- 1366. DOI: 10.13192/j.ljtcm.2011.07.118.huanggy.032.
    [21] WANG N, WANG MG, MAO DW, et al. Clinical observation of rhubarb decoction in the treatment of type A hepatic encephalopathy[J]. Lishizhen Med Mater Med Res, 2015, 26( 5): 1169- 1171. DOI: 10.3969/j.issn.1008-0805.2015.05.053.

    王娜, 王明刚, 毛德文, 等. 大黄煎剂治疗A型肝性脑病的临床疗效观察[J]. 时珍国医国药, 2015, 26( 5): 1169- 1171. DOI: 10.3969/j.issn.1008-0805.2015.05.053.
    [22] QIU H, HUANG GY, MAO DW, et al. Orthoplan to screen the optimum scheme of retention Enema in treatment of hepatic encephalopathy with rhubarb decoction[J]. J Tradit Chin Med, 2010, 51( 11): 990- 992. DOI: 10.13288/j.11-2166/r.2010.11.011.

    邱华, 黄古叶, 毛德文, 等. 正交设计筛选大黄煎剂保留灌肠治疗肝性脑病最佳方案的研究[J]. 中医杂志, 2010, 51( 11): 990- 992. DOI: 10.13288/j.11-2166/r.2010.11.011.
    [23] TAN LC. Observation and nursing care of rhubarb decoction retention Enema in the treatment of hepatic encephalopathy[J]. Liaoning J Tradit Chin Med, 2007, 34( 8): 1116- 1117. DOI: 10.13192/j.ljtcm.2007.08.96.tanlch.051.

    谭柳纯. 大黄煎剂保留灌肠治疗肝性脑病疗效观察及护理[J]. 辽宁中医杂志, 2007, 34( 8): 1116- 1117. DOI: 10.13192/j.ljtcm.2007.08.96.tanlch.051.
    [24] WU FL, LIAO NS, WEI JR, et al. Research progress of technical specification of the treatment of hepatic encephalopathy by Dahuang Decoction retention Enema[J]. West J Tradit Chin Med, 2023, 36( 6): 141- 144. DOI: 10.12174/j.issn.2096-9600.2023.06.34.

    吴凤兰, 廖南盛, 卫家润, 等. 大黄煎剂保留灌肠治疗肝性脑病的技术规范研究进展[J]. 西部中医药, 2023, 36( 6): 141- 144. DOI: 10.12174/j.issn.2096-9600.2023.06.34.
    [25] ZHANG GF, CAI YY, LIN L, et al. Protective mechanism of rhubarb decoction against inflammatory damage of brain tissue in rats with mild hepatic encephalopathy: A study based on the PI3K/AKT/mTOR signaling pathway[J]. J Clin Hepatol, 2024, 40( 2): 312- 318. DOI: 10.12449/JCH240215.

    张广发, 蔡颖莹, 林龙, 等. 基于PI3K/AKT/mTOR信号通路探讨大黄煎剂对轻微型肝性脑病大鼠脑组织炎症损伤的保护机制[J]. 临床肝胆病杂志, 2024, 40( 2): 312- 318. DOI: 10.12449/JCH240215.
    [26] DU YQ, WANG M, XU J, et al. Investigation of therapeutic effects of rhubarb decoction retention Enema on minimal hepatic encephalopathy in rats based on 16S rDNA gene sequencing and bile acid metabolomics[J]. J Pharm Biomed Anal, 2023, 230: 115392. DOI: 10.1016/j.jpba.2023.115392.
    [27] DU YQ, WANG M, HUANG GC, et al. Therapeutic effect of retention Enema with compound rhubarb decoction on a rat model of minimal hepatic encephalopathy based on bile acid metabolomics[J]. J Clin Hepatol, 2023, 39( 10): 2348- 2357. DOI: 10.3969/j.issn.1001-5256.2023.10.012.

    杜沅沁, 王萌, 黄国初, 等. 基于胆汁酸代谢组学探讨复方大黄煎剂保留灌肠对轻微型肝性脑病大鼠模型的治疗作用[J]. 临床肝胆病杂志, 2023, 39( 10): 2348- 2357. DOI: 10.3969/j.issn.1001-5256.2023.10.012.
    [28] YAO C, HUANG GC, WANG M, et al. Chinese herbal medicine formula jieduhuayu granules improves cognitive and neurophysiological functions in patients with cirrhosis who have minimal hepatic encephalopathy: A randomized controlled trial[J]. Complement Ther Med, 2014, 22( 6): 977- 985. DOI: 10.1016/j.ctim.2014.10.005.
    [29] YAO C, WANG M, YAO F, et al. Clinical observation on intelligence test and neurophysiological changes of patients with mild hepatic encephalopathy treated with Jiedu Huayu recipe[J]. Lishizhen Med Mater Med Res, 2014, 25( 4): 890- 892. DOI: 10.3969/j.issn.1008-0805.2014.04.052.

    姚春, 王萌, 姚凡, 等. 解毒化瘀方对轻微型肝性脑病患者智力测验及神经电生理学改变的临床观察[J]. 时珍国医国药, 2014, 25( 4): 890- 892. DOI: 10.3969/j.issn.1008-0805.2014.04.052.
    [30] MAO DW, QIU H, HUANG GY, et al. Experimental study on mechanism of detoxification and removing blood stasis formula II in preventing and treating hepatic encephalopathy in rats with AHG[J]. Tianjin J Tradit Chin Med, 2006, 23( 6): 486- 489. DOI: 10.3969/j.issn.1672-1519.2006.06.016.

    毛德文, 邱华, 黄古叶, 等. 解毒化瘀Ⅱ方防治急性肝衰竭肝性脑病的实验机制研究[J]. 天津中医药, 2006, 23( 6): 486- 489. DOI: 10.3969/j.issn.1672-1519.2006.06.016.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 本文二维码
图(1)
计量
  • 文章访问数:  1111
  • HTML全文浏览量:  53
  • PDF下载量:  10
  • 被引次数: 0
出版历程
  • 收稿日期:  2024-05-29
  • 录用日期:  2024-06-24
  • 出版日期:  2025-02-25
  • 分享

    • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回
        

    中国首个肝胆病专业杂志

    主管单位：中华人民共和国教育部

    主办单位：吉林大学

    学术支持：中华医学会肝病学分会

    通信地址：长春市新疆街461号

    投稿咨询：0431-88782044

    审稿咨询：0431-88783542

    电子信箱：lcgdb@vip.163.com

    关于本刊

    投稿指南

    在线期刊

    肝胆学院

    指南共识

    昨日IP[]昨日PV[]今日IP[]今日PV[]当前在线[]

    网站设计 © 2020 《临床肝胆病杂志》编辑部 吉ICP备10000617号-1 技术支持: 仁和软件   百度统计